{"title": "Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor", "doi": "10.1101/2020.02.19.956235", "citation_id": "2020.02.19.956235v1", "date": "2020-02-20", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.02.19.956235", "abstract": "<p>A novel and highly pathogenic coronavirus (2019-nCoV) has caused an outbreak in Wuhan city, Hubei province of China since December 2019, and soon spread nationwide and spilled over to other countries around the world. To better understand the initial step of infection at atomic-level, we determined the crystal structure of the 2019-nCoV spike receptor-binding domain (RBD) bound with the cell receptor ACE2 at 2.45 angstrom resolution. The overall ACE2-binding mode of the 2019-nCoV RBD is nearly identical to that of the SARS-CoV RBD, which also utilizes ACE2 as the cell receptor. Structural analysis identified residues in 2019-nCoV RBD critical for ACE2 binding, and majority of which are either highly conserved or shared similar side chain properties with those in the SARS-CoV RBD. Such similarity in structure and sequence strongly argue for a convergent evolution between 2019-nCoV and SARS-CoV RBD for improved binding to ACE2 despite of being segregated in different genetic lineages in the betacoronavirus genus. The epitopes of two SARS-CoV antibodies targeting the RBD are also analyzed with the 2019-nCoV RBD, providing insights into future identification of cross-reactive antibodies.</p>", "twitter_description": "A novel and highly pathogenic coronavirus (2019-nCoV) has caused an outbreak in Wuhan city, Hubei province of China since December 2019, and soon spread nationwide and spilled over to other countries around the world. To better understand the initial step of infection at atomic-level, we determined the crystal structure of the 2019-nCoV spike receptor-binding domain (RBD) bound with the cell receptor ACE2 at 2.45 \u00c5 resolution. The overall ACE2-binding mode of the 2019-nCoV RBD is nearly identical to that of the SARS-CoV RBD, which also utilizes ACE2 as the cell receptor. Structural analysis identified residues in 2019-nCoV RBD critical for ACE2 binding, and majority of which are either highly conserved or shared similar side chain properties with those in the SARS-CoV RBD. Such similarity in structure and sequence strongly argue for a convergent evolution between 2019-nCoV and SARS-CoV RBD for improved binding to ACE2 despite of being segregated in different genetic lineages in the betacoronavirus genus. The epitopes of two SARS-CoV antibodies targeting the RBD are also analyzed with the 2019-nCoV RBD, providing insights into future identification of cross-reactive antibodies.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.19.956235v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.02.19.956235v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.19.956235v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/02/20/2020.02.19.956235.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.02.19.956235v1", "access_rights": "restricted", "authors": ["Jun Lan", "Jiwan Ge", "Jinfang Yu", "Sisi Shan", "Huan Zhou", "Shilong Fan", "Qi Zhang", "Xuanling Shi", "Qisheng Wang", "Linqi Zhang", "Xinquan Wang"]}